Enhancing SKIN health and safety in aged CARE: An exploratory cluster randomized pragmatic trial in aged nursing home residents (SKINCARE)

Conditions

Skin health in nursing home residents, especially: Pressure ulcer, xerosis cutis (dry skin), incontinence-associated dermatitis, skin tears and intertrigo. L89 L85.3 L30.4

Bettina Völzer, Monira El Genedy‐Kalyoncu, Alexandra Fastner, Tsenka Tomova‐Simitchieva, Konrad Neumann et al. (11 authors)

International Journal of Nursing Studies2023-10-2811 citations

10.1016/j.ijnurstu.2023.104627

Prevalence and associations of xerosis cutis, incontinence-associated dermatitis, skin tears, pressure ulcers, and intertrigo in aged nursing home residents: A representative prevalence study

Bettina Völzer, Monira El Genedy‐Kalyoncu, Alexandra Fastner, Tsenka Tomova-Simitchieva, Konrad Neumann et al. (8 authors)

International Journal of Nursing Studies2023-02-2244 citations

10.1016/j.ijnurstu.2023.104472

Enhancing SKIN health and safety in aged CARE (SKINCARE Trial): a study protocol for an exploratory cluster-randomized pragmatic trial.

Kottner J, Hahnel E, El Genedy M, Neumann K, Balzer K.

2019-05-2912 citations

10.1186/s13063-019-3375-7

Interventions

Group 1: Experimental intervention: Interventions on nursing home level: - Adaption of skin care algorithm to local conditions and requirements - Educational sessions for nurses and other care givers

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Being resident of the respective nursing home 2. Being 65+ years old 3. Care degree 2 or higher (according to the German Social Code Book XI) 4. Written informed consent given by themselves or on their behalf by legal representatives

Exclusion criteria

Exclusion criteria: 1. Residents at the end of life (dying persons) 2. Any dermatological condition or skin affection requiring dermatological treatment 3. Known intolerances to any possible irritating product ingredients, e.g. urea or lactate buffer or known hypersensitivity to any product ingredients e.g. sorbid acid or cetylstearyl alcohol.

Design outcomes

Primary

Measure	Time frame
No distinction is made between primary and secondary outcomes. The concept of efficacy also does not apply in this pragmatic exploratory study. Clinical outcomes include the cumulative incidence of pressures ulcers, incontinence-associated dermatitis, intertrigo, skin tears and the severity of dry skin. Skin barrier characteristics (pH, stratum corneum hydration, transepidermal water loss) will be measured. Patient reported outcomes include quality of life (WHO-Five Wellbeing Index for cognitiv healthy residents, QUALIDEM tool for cognitiv impaired residents), itch (5-D itch scale for cognitiv healthy residents) and pain (numeric rating scale for cognitiv healthy residents, verbal rating scale for cognitiv impaired residents). All outcomes will be measured at week 0 (baseline), week 12 +/- 1 and week 24 +/- 1 (end of study).	—

Measure

Time frame

No distinction is made between primary and secondary outcomes. The concept of efficacy also does not apply in this pragmatic exploratory study. Clinical outcomes include the cumulative incidence of pressures ulcers, incontinence-associated dermatitis, intertrigo, skin tears and the severity of dry skin. Skin barrier characteristics (pH, stratum corneum hydration, transepidermal water loss) will be measured. Patient reported outcomes include quality of life (WHO-Five Wellbeing Index for cognitiv healthy residents, QUALIDEM tool for cognitiv impaired residents), itch (5-D itch scale for cognitiv healthy residents) and pain (numeric rating scale for cognitiv healthy residents, verbal rating scale for cognitiv impaired residents). All outcomes will be measured at week 0 (baseline), week 12 +/- 1 and week 24 +/- 1 (end of study).

—

Secondary

Measure	Time frame
No distinction is made between primary and secondary outcomes.	—

Countries

Germany

Contacts

Public ContactJan Kottner

Institut für Klinische Pflegewissenschaft, Charité – Universitätsmedizin Berlin

jan.kottner@charite.de+49 (0)30 450 529 411

Outcome results

None listed